[go: up one dir, main page]

CY1120800T1 - Μεθοδοι και συνθεσεις για την in vivo ενεργοποιηση του σχηματισμου παγκρεατικων βητα κυτταρων - Google Patents

Μεθοδοι και συνθεσεις για την in vivo ενεργοποιηση του σχηματισμου παγκρεατικων βητα κυτταρων

Info

Publication number
CY1120800T1
CY1120800T1 CY181100753T CY181100753T CY1120800T1 CY 1120800 T1 CY1120800 T1 CY 1120800T1 CY 181100753 T CY181100753 T CY 181100753T CY 181100753 T CY181100753 T CY 181100753T CY 1120800 T1 CY1120800 T1 CY 1120800T1
Authority
CY
Cyprus
Prior art keywords
beta cell
compositions
methods
cell formation
pancreatic beta
Prior art date
Application number
CY181100753T
Other languages
English (en)
Inventor
Bruno Doiron
Ralph A Defronzo
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Publication of CY1120800T1 publication Critical patent/CY1120800T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/01—Phosphotransferases with an alcohol group as acceptor (2.7.1)
    • C12Y207/01002—Glucokinase (2.7.1.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03048—Protein-tyrosine-phosphatase (3.1.3.48)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/50—Biochemical production, i.e. in a transformed host cell
    • C12N2330/51—Specially adapted vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)

Abstract

Οι υλοποιήσεις της εφεύρεσης διεγείρουν τρία επίπεδα φυσιολογίας των βήτα κυττάρων: (i) μεταβολισμό γλυκόζης, (ii) λειτουργία υποδοχέα μεμβράνης, και (iii) παράγοντες μεταγραφής που οδηγούν στον in vivo σχηματισμό βήτα κυττάρων στο πάγκρεας με σκοπό τη θεραπευτική αντιμετώπιση του διαβήτη. Σε ορισμένες όψεις, οι μέθοδοι περιλαμβάνουν την ενσωμάτωση τριών επιπέδων κυτταρικής φυσιολογίας: μεταβολισμό, λειτουργία υποδοχέα μεμβράνης και γονιδιακή μεταγραφή. Η ενσωμάτωση πολλαπλών επιπέδων κυτταρικής φυσιολογίας παράγει μια συνεργιστική επίδραση στον σχηματισμό βήτα κυττάρων.
CY181100753T 2012-07-31 2018-07-18 Μεθοδοι και συνθεσεις για την in vivo ενεργοποιηση του σχηματισμου παγκρεατικων βητα κυτταρων CY1120800T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261678077P 2012-07-31 2012-07-31
PCT/US2013/052820 WO2014022455A1 (en) 2012-07-31 2013-07-31 Methods and compositions for in vivo induction of pancreatic beta cell formation

Publications (1)

Publication Number Publication Date
CY1120800T1 true CY1120800T1 (el) 2019-12-11

Family

ID=50028488

Family Applications (1)

Application Number Title Priority Date Filing Date
CY181100753T CY1120800T1 (el) 2012-07-31 2018-07-18 Μεθοδοι και συνθεσεις για την in vivo ενεργοποιηση του σχηματισμου παγκρεατικων βητα κυτταρων

Country Status (19)

Country Link
US (3) US9649344B2 (el)
EP (1) EP2880167B1 (el)
JP (2) JP6371765B2 (el)
KR (1) KR102100093B1 (el)
CN (1) CN104736711B (el)
BR (1) BR112015002295B1 (el)
CA (2) CA2880691C (el)
CY (1) CY1120800T1 (el)
DK (1) DK2880167T3 (el)
ES (1) ES2679394T3 (el)
HR (1) HRP20181124T1 (el)
HU (1) HUE039520T2 (el)
LT (1) LT2880167T (el)
MX (1) MX360824B (el)
PL (1) PL2880167T3 (el)
PT (1) PT2880167T (el)
SI (1) SI2880167T1 (el)
SM (1) SMT201800404T1 (el)
WO (1) WO2014022455A1 (el)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007237096C1 (en) 2006-04-07 2012-12-13 EyePoint Pharmaceuticals, Inc. Antibodies that bind human protein tyrosine phosphatase beta (HPTPbeta) and uses thereof
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
AU2010271105C1 (en) 2009-01-12 2014-08-21 Aerpio Therapeutics, Inc. Compounds, compositions, and methods for preventing metastasis of cancer cells
MX363351B (es) 2011-10-13 2019-03-20 Aerpio Therapeutics Inc Un agente de unión a hptp?-ecd para usarse en el tratamiento de síndrome de fuga vascular.
CA2880691C (en) * 2012-07-31 2018-09-04 The Board Of Regents Of The University Of Texas System Methods and compositions for in vivo induction of pancreatic beta cell formation
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
CN106456614A (zh) 2014-03-14 2017-02-22 爱尔皮奥治疗有限公司 HPTP‑β抑制剂
CA2998673C (en) 2015-09-23 2023-12-12 Aerpio Therapeutics, Inc. Methods of treating intraocular pressure with activators of tie-2
KR20220122636A (ko) * 2019-12-30 2022-09-02 유니버시티 오브 피츠버그-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 제1형 당뇨병을 치료하기 위한 대식세포의 췌장 내 m2 분극화
WO2023039164A2 (en) * 2021-09-09 2023-03-16 Flagship Pioneering Innovations Vi, Llc Methods and compositions for modulating goblet cells and for muco-obstructive diseases
WO2023225603A2 (en) * 2022-05-20 2023-11-23 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Insulin promoter for gene therapy for type 2 diabetes mellitus

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
EP0273085A1 (en) 1986-12-29 1988-07-06 IntraCel Corporation A method for internalizing nucleic acids into eukaryotic cells
US5550318A (en) 1990-04-17 1996-08-27 Dekalb Genetics Corporation Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof
US5484956A (en) 1990-01-22 1996-01-16 Dekalb Genetics Corporation Fertile transgenic Zea mays plant comprising heterologous DNA encoding Bacillus thuringiensis endotoxin
US5383848A (en) 1990-04-12 1995-01-24 Gensia, Inc. Iontophoretic administration of drugs
US5610042A (en) 1991-10-07 1997-03-11 Ciba-Geigy Corporation Methods for stable transformation of wheat
GB9222888D0 (en) 1992-10-30 1992-12-16 British Tech Group Tomography
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US6087129A (en) * 1996-01-19 2000-07-11 Betagene, Inc. Recombinant expression of proteins from secretory cell lines
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
US6261840B1 (en) * 2000-01-18 2001-07-17 Isis Pharmaceuticals, Inc. Antisense modulation of PTP1B expression
JP2003189875A (ja) * 2001-12-28 2003-07-08 Japan Science & Technology Corp 膵β細胞関連転写因子の遺伝子導入によるインスリン産生細胞の形成誘導
DE60328671D1 (de) 2002-03-26 2009-09-17 Banyu Pharma Co Ltd Neue aminobenzamidderivate
JP4136434B2 (ja) 2002-04-17 2008-08-20 進 清野 インスリン産生細胞の誘導
GB0227813D0 (en) * 2002-11-29 2003-01-08 Astrazeneca Ab Chemical compounds
US20080247476A1 (en) 2005-07-20 2008-10-09 Nxp B.V. Method and Synchronizer for Fine Ofdm Symbol Synchronization and Method/Receiver for the Reception of Ofdm Symbols
JP2007061096A (ja) 2005-08-31 2007-03-15 Lifescan Inc 細胞分化を促進する方法
WO2007075847A2 (en) 2005-12-20 2007-07-05 Takeda Pharmaceutical Company Limited Glucokinase activators
JP5190448B2 (ja) 2006-04-20 2013-04-24 ファイザー・プロダクツ・インク グルコキナーゼ仲介疾患を予防および治療するための縮合フェニルアミド複素環化合物
EP2173717B9 (en) 2007-07-27 2013-06-26 Bristol-Myers Squibb Company Novel glucokinase activators and methods of using same
US9683215B2 (en) 2008-08-22 2017-06-20 President And Fellows Of Harvard College Methods of reprogramming cells
EP2393926A1 (en) 2009-02-03 2011-12-14 F. Hoffmann-La Roche AG Compositions and methods for inhibiting expression of ptp1b genes
AU2011311344B2 (en) 2010-10-08 2016-09-08 Mina Therapeutics Limited Short RNA molecules
CA2880691C (en) * 2012-07-31 2018-09-04 The Board Of Regents Of The University Of Texas System Methods and compositions for in vivo induction of pancreatic beta cell formation

Also Published As

Publication number Publication date
ES2679394T3 (es) 2018-08-27
WO2014022455A1 (en) 2014-02-06
BR112015002295A2 (pt) 2018-05-08
US10293002B2 (en) 2019-05-21
JP6666961B2 (ja) 2020-03-18
PL2880167T3 (pl) 2018-12-31
MX360824B (es) 2018-11-15
CA3012929A1 (en) 2014-02-06
KR102100093B1 (ko) 2020-05-15
KR20150038531A (ko) 2015-04-08
SI2880167T1 (sl) 2018-12-31
PT2880167T (pt) 2018-07-23
SMT201800404T1 (it) 2018-09-13
LT2880167T (lt) 2018-10-25
US20190307809A1 (en) 2019-10-10
US20150190432A1 (en) 2015-07-09
BR112015002295B1 (pt) 2022-02-01
HRP20181124T1 (hr) 2018-11-02
JP2018172430A (ja) 2018-11-08
JP2015526432A (ja) 2015-09-10
US9649344B2 (en) 2017-05-16
CN104736711A (zh) 2015-06-24
EP2880167A1 (en) 2015-06-10
US10980841B2 (en) 2021-04-20
CA2880691C (en) 2018-09-04
MX2015001448A (es) 2015-07-14
JP6371765B2 (ja) 2018-08-08
EP2880167B1 (en) 2018-04-18
US20170312318A1 (en) 2017-11-02
HUE039520T2 (hu) 2019-01-28
CA2880691A1 (en) 2014-02-06
EP2880167A4 (en) 2016-03-30
CA3012929C (en) 2023-01-17
DK2880167T3 (en) 2018-07-30
CN104736711B (zh) 2017-09-08

Similar Documents

Publication Publication Date Title
CY1120800T1 (el) Μεθοδοι και συνθεσεις για την in vivo ενεργοποιηση του σχηματισμου παγκρεατικων βητα κυτταρων
CY1123831T1 (el) Γενετικως τροποποιημενοι ποντικοι υποδοχεα τ κυτταρων
CY1121014T1 (el) ΝΕΑ ΔΟΜΙΚΑ ΣΧΕΔΙΑΜΕΝΑ shRNA
CY1123142T1 (el) Βελτιωμενες μεθοδοι για την παραγωγη θετων κυτταρικων θεραπειων
TR201908404T4 (tr) İşlenmiş yüksek afinite insan t hücresi reseptörleri.
BR112013003160A2 (pt) tratamento de diabetes com células precursoras endócrinas pancráticas
EA201991369A1 (ru) Модифицированные направляющие рнк
DK2276832T3 (da) Dendritisk plasmacytoid cellelinje, der anvendes i aktiv eller adoptiv celleterapi
EA201300454A1 (ru) Клетка дрожжей, сбраживающая пентозу и глюкозу
IN2012DN02710A (el)
CL2015000529A1 (es) Inhibidores de glucosilceramida sintasa.
CL2009000393A1 (es) Composición farmaceutica que comprende a) un agente farmaceutico activable, b) un agente activo plasmonico; util para el tratamiento de trastornos de proliferación celular.
UA115652C2 (uk) Сполука, що містить модифікований олігонуклеотид, комплементарна mir-21
MX350966B (es) Celulas madre pluripotentes.
MX2021008465A (es) Farmaco-enlazadores modificados con polietilenglicol para la farmacocinetica mejorada de conjugados de ligando-farmaco.
CY1116803T1 (el) Φαρμακευτικος συνδυασμος για χρηση στον γλυκαιμικο ελεγχο σε ασθενεις με διαβητη τυπου 2
MX2014005710A (es) Un metodo de cribado de farmaco y usos del mismo.
MX2016017317A (es) Metodos y composiciones para modificaciones geneticas dirigidas y metodos de uso.
CL2008001124A1 (es) Formulacion farmaceutica que comprende al menos un derivado de acido lipoico y un reactivo formador de par ionico, util en el tratamiento del cancer.
CL2015003580A1 (es) Conjugados de suministro de polinucleotidos in vivo que tienen acoplamientos sensibles a enzima.
DOP2013000209A (es) Inhibidores de glucosilceramida sintasa
EA201290602A1 (ru) КОМПОЗИЦИИ ДЛЯ НАПРАВЛЕННОЙ ДОСТАВКИ МАЛЫХ ИНТЕРФЕРИРУЮЩИХ РНК (миРНК)
EP4458361A3 (en) Modulation of ube3a-ats expression
MX366369B (es) Metodo para un ensayo de deteccion de farmacos basado en celulas y el uso del mismo.
CY1121787T1 (el) Sirna και χρηση αυτων σε μεθοδους και συνθεσεις για τη θεραπεια ή/και προληψη οφθαλμικων καταστασεων